본문 바로가기

Clinical Trial

  • home
  • R&D
  • Clinical Trial

Innovative Drug

이 표는 수집하는 개인정보 항목 및 수집방법, 개인정보의 수집목적 및 이용목적, 개인정보의 공유 및 제공, 수집한 개인정보 처리 위탁, 수집한 개인정보의 보유 및 이용기간, 개인정보 파기절차 및 방법, 이용자 및 법정대리인의 권리와 그 행사방법, 쿠키의 운영과 활용(자동수집장치 설치, 운영, 거부에 관한 사항), 개인정보 보호를 위한 이용자의 주의사항, 개인정보 관리 책임자, 부칙 구성되어 있습니다.
Product/Project Name Target Indication Title Stage ClinicalTrials.gov
Identifier:
S-217622 Covid-19 A Phase 2/3 Study of S-217622 in Participants Infected with SARS-CoV-2 Phase 2/3 -
IDG-16177 Type 2 DM A Placebo- and Active-controlled, Randomised, Double-blind, Dose escalation Phase I Study of IDG-16177 for the Evaluation of its Safety and Pharmacokinetics with the Exploration on its Pharmacodynamics and Efficacy Phase 1 NCT04982705
ID119031166 NASH A Placebo-controlled, Randomized, Double-blind, Single and Multiple Dose-escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of ID119031166M with the Exploration of Pharmacodynamic Effects in Healthy Participants  Phase 1 -
Besivo
(Besifovir dipivoxil maleate)
Hepatitis B A phase Ⅲ, multi-center, randomized, double-blinded, parallel study to assess the antiviral activity and safety of Besifovir 150 mg compared to Tenofovir 300 mg in chronic hepatitis B patients Phase 3 NCT01937806
Pilot study to assess the antiviral activity and safety of Besifovir dipivoxil 150mg and L-carnitine 660mg compared to Tenofovir Alafenamide 25mg in chronic hepatitis B patients with Nonalcoholic fatty liver Phase 4 NCT03604016
A Randomized, Open-Label, Parallel, Multi-Center, Non-inferiority, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Switching to Besifovir dipivoxil maleate from Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients Who Pretreated with Tenofovir Disoproxil Fumarate Phase 4 NCT04202536



TOP